Results & Expectations

What Affects Results?

Learn what affects weight loss results on Mounjaro and Wegovy, including dose, consistency, lifestyle, and individual response.

Whether you have hit a slower stretch on Mounjaro or Wegovy and want to understand why, or are starting treatment and trying to set yourself up well, this guide covers the factors that shift individual weight-loss results above or below the trial averages. Some are within your control, some are not, and most are worth a conversation with your prescriber. LetsLoseWeight is an independent comparison site; we do not prescribe medication, and the information below is for context, not personal medical advice.

Why averages mask wide individual variation

The published trial averages — around 21% on Mounjaro 15mg, around 15% on Wegovy 2.4mg — compress a wide spread of outcomes. Around 9–14% of trial participants did not lose 5% even at the highest doses; a similar proportion lost more than 25%. The factors below explain a lot of that spread.

For the headline numbers and the spread, see our how much weight can you lose guide.

Factors largely within your control

Adherence to the injection schedule

The biggest avoidable cause of below-average results is missed doses. The medicines work because they keep GLP-1 (and, for Mounjaro, GIP) signalling continuously active. Missed weeks let the signal drop, and the appetite-suppressing effect with it.

The licence allows for some flexibility — Mounjaro can be taken up to 96 hours late on the same dose; Wegovy up to 48 hours late — but more than two consecutive missed doses usually require dropping back a level. See our missed dose guide.

Calorie intake

Both medicines are licensed as adjuncts to a reduced-calorie diet. They reduce appetite, but they cannot fully override active overeating. Two patients on the same dose can produce very different results if one is in a 500-kcal-per-day deficit and the other is roughly maintaining.

In the SURMOUNT and STEP trials, all participants followed structured dietary support. Real-world patients without that support often produce lower-than-trial results, and a portion of that difference is the missing dietary component.

Protein intake and muscle preservation

People eating very little protein during weight loss tend to lose more muscle and less fat than those eating adequate protein. Muscle loss makes the scale move faster (water and tissue), but the result on body composition is worse — and lower muscle mass means lower resting energy expenditure, which makes maintenance harder.

A common target is 1.2–1.6g protein per kg of body weight per day, spread across meals. For someone on a reduced calorie intake, hitting that target may require deliberate planning.

Physical activity

Activity supports weight loss, muscle preservation, mood, and longer-term maintenance. The trial protocols included activity targets (typically 150 minutes per week of moderate activity, or equivalent). Patients who hit those targets typically did better than those who did not.

Resistance training in particular helps preserve muscle through weight loss. Walking, cycling and other activity adds to the calorie deficit and improves cardiovascular health on the same timeline as the medicine's other benefits.

Sleep

Inadequate sleep — typically less than 6–7 hours regularly — is associated with lower weight-loss success in observational research. Sleep affects appetite-regulating hormones, glucose tolerance, and adherence to lifestyle changes. Improving sleep is one of the most underrated supports for treatment.

Alcohol

Alcohol is calorie-dense (around 7 kcal/g), often consumed in addition to food rather than instead of it, and lowers inhibition around eating. Patients who drink heavily during treatment often see lower-than-expected results. Alcohol also worsens nausea on these medicines and can complicate blood-sugar management for those with type 2 diabetes.

Factors partially within your control

Whether you tolerate the higher doses

Tolerability is partly biology and partly how titration is managed. Patients who manage to step up to the higher Mounjaro doses (10–15mg) or to the full Wegovy 2.4mg often see larger weight loss than those who plateau on lower doses.

Slow titration, dietary adjustments, and patient communication with the prescriber can all help. Some patients genuinely cannot tolerate the highest doses; for them, settling at a lower maintenance dose is the right call.

Other medications

Some commonly prescribed medicines can promote weight gain or blunt weight-loss treatment:

  • Some antidepressants — particularly mirtazapine, paroxetine, some tricyclics
  • Some antipsychotics — olanzapine, clozapine, quetiapine
  • Some diabetes medicines — insulin, sulfonylureas, pioglitazone
  • Some steroid courses — particularly long-term oral corticosteroids
  • Beta-blockers can blunt some of the metabolic effects

This does not mean these medicines should be stopped — many are essential — but they may explain a slower-than-expected response and warrant a conversation with the prescriber.

Stress

Chronic stress elevates cortisol, which affects appetite, sleep, and visceral fat distribution. Patients under sustained high stress sometimes see slower or stalled weight loss. Stress reduction strategies — mindfulness, exercise, social connection, professional support if needed — feature in NICE guidance for obesity care for this reason.

Factors largely outside your control

Starting weight and body composition

Higher starting BMI tends to be associated with greater absolute weight loss but similar or lower percentage loss. Body composition (lean mass vs fat mass) varies between individuals and affects energy expenditure independently.

Genetics and individual biology

A meaningful proportion of weight-loss-injection non-response is biological. Researchers are still characterising the genetic and metabolic factors that predict response. There is no commercially available test that will tell you in advance whether you will be a strong, average, or weak responder; the answer comes from the first 12 weeks of treatment at the maintenance dose.

Age

Older adults sometimes lose somewhat less than younger adults, partly because of lower muscle mass, lower physical activity, and slower metabolic adaptation. The effect is modest in trials.

Sex

Women tend to lose somewhat less weight in absolute terms than men in trials, partly because they typically start at lower weights. As a percentage, results are broadly similar.

Underlying medical conditions

Several conditions can blunt weight-loss response:

  • Type 2 diabetes — average weight loss tends to be lower than in non-diabetic populations
  • Hypothyroidism — particularly if not adequately treated
  • PCOS — may slightly reduce response in some women
  • Sleep apnoea — when untreated, can worsen the metabolic environment
  • Chronic kidney disease, liver disease, severe heart failure — may affect response and require closer monitoring

Some of these are addressable; others are part of the picture. Discuss with your prescriber.

When to be concerned and what to do

A reasonable benchmark from clinical practice is at least 5% weight loss by 12 weeks at the maintenance dose. If your trajectory is below that, the prescriber will usually want to:

  • Review adherence — are injections being taken consistently
  • Review dose — could it be titrated higher
  • Review other medications — any candidates for weight-promoting effects
  • Screen for underlying conditions — thyroid, sleep apnoea, mental health
  • Review diet and activity — is the lifestyle component genuinely happening
  • Consider switching — sometimes a switch from Wegovy to Mounjaro or vice versa unlocks progress

For more on plateaus specifically, see our plateau guide.

What you can do this week

If you want to shift your trajectory upwards, the highest-leverage practical changes are usually:

  • Tighten injection schedule — same day each week, ideally the same time
  • Increase protein — aim for around 1.2–1.6g per kg body weight per day
  • Move more — walking and resistance training are the easiest additions
  • Reduce alcohol — even moderate reduction often shifts results
  • Track sleep — aim for consistent 7+ hours
  • Talk to your prescriber about dose titration if you have not yet reached the maximum tolerable dose

These are not glamorous and they don't promise dramatic transformation. But they consistently move individual results, where dramatic claims do not.

Frequently asked questions

Why are my results worse than my friend's?
A combination of factors above — dose, adherence, lifestyle, individual biology, other medications, underlying conditions. Comparing to others is rarely useful; comparing to your own trajectory over time is.

Can I do anything about being a non-responder?
Possibly. Up to a point, what looks like non-response is actually under-dosing or undiagnosed contributors (thyroid, sleep apnoea, weight-promoting medicines). Up to 12 weeks at the maintenance dose with everything optimised is the usual benchmark before considering alternatives.

Does menstrual cycle affect results?
The cycle can shift the scale by 1–3kg through fluid retention, which can mask real changes. The trend over a month tends to show the underlying picture.

Can I increase the dose to lose more?
Higher doses produce greater average weight loss with diminishing returns at the top. Going beyond the licensed maximum is not licensed and a regulated UK pharmacy will not do it. Within the licensed range, talk to your prescriber about titration.

Next steps

Sources

This guide is for general information only and is not a substitute for professional medical advice. Talk to your prescriber about factors specific to your situation.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Guides
What Affects Weight Loss Injection Results UK | LetsLoseWeight